Metabolic disorders (diabetes and obesity) induce various organ dysfunction of the whole body. Typical complications of diabetes and obesity include vascular injury, metabolic heart disease, diabetic kidney disease, diabetic retinopathy. The pulmonary system was observed as a target of diabetes and obesity since decades ago. Increasing clinical and experimental evidence indicates that the pulmonary system serves a critical target of the metabolic disorders. Metabolic disorders increase the risk of pulmonary fibrosis, pulmonary microvascular disease, chronic obstructive pulmonary disease (COPD), asthma,lung cancer, pulmonary arterial hypertension (PAH) in human. Despite the level of understanding has progressed considerably in the past decades, the pathogenesis of the metabolic pulmonary diseases remains largely unknown
This Research Topic aims to provide an updated clinical and mechanism overview of metabolic disorders effects on pulmonary function, injury, immune response, and regeneration. We welcome authors to contribute original research articles as well as review articles that focus on the topic of Diabetes and Obesity Effects on Pulmonary Function.
Potential sub-topics include, but are not limited to:
- The clinical study of pulmonary disorders (e.g. Fibrosis, COPD, Asthma) in diabetic and obese patients;
- Molecular and cellular mechanisms (e.g., Inflammation, Oxidative Stress) regulating pulmonary function in metabolic disorders;
- Immune response (infection) affected by metabolic disorders in the lung; and
- Effects of metabolic disorders on lung injury, repair, and regeneration.
Conflict of Interests Statement:
The Topic Editor Albert Lecube joined an Investigator Sponsored Study (ISS) from Novo Nordisk related with the potential effects of liraglutide on lung function and sleep breathing in type 2 diabetes: "MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CROSS-OVER PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG)". ClinicalTrials.gov: NCT02889510
Metabolic disorders (diabetes and obesity) induce various organ dysfunction of the whole body. Typical complications of diabetes and obesity include vascular injury, metabolic heart disease, diabetic kidney disease, diabetic retinopathy. The pulmonary system was observed as a target of diabetes and obesity since decades ago. Increasing clinical and experimental evidence indicates that the pulmonary system serves a critical target of the metabolic disorders. Metabolic disorders increase the risk of pulmonary fibrosis, pulmonary microvascular disease, chronic obstructive pulmonary disease (COPD), asthma,lung cancer, pulmonary arterial hypertension (PAH) in human. Despite the level of understanding has progressed considerably in the past decades, the pathogenesis of the metabolic pulmonary diseases remains largely unknown
This Research Topic aims to provide an updated clinical and mechanism overview of metabolic disorders effects on pulmonary function, injury, immune response, and regeneration. We welcome authors to contribute original research articles as well as review articles that focus on the topic of Diabetes and Obesity Effects on Pulmonary Function.
Potential sub-topics include, but are not limited to:
- The clinical study of pulmonary disorders (e.g. Fibrosis, COPD, Asthma) in diabetic and obese patients;
- Molecular and cellular mechanisms (e.g., Inflammation, Oxidative Stress) regulating pulmonary function in metabolic disorders;
- Immune response (infection) affected by metabolic disorders in the lung; and
- Effects of metabolic disorders on lung injury, repair, and regeneration.
Conflict of Interests Statement:
The Topic Editor Albert Lecube joined an Investigator Sponsored Study (ISS) from Novo Nordisk related with the potential effects of liraglutide on lung function and sleep breathing in type 2 diabetes: "MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CROSS-OVER PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG)". ClinicalTrials.gov: NCT02889510
